Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Abstract

Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS G12C-mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC). Between 15 September 2022 and 28 September 2023, 119 patients with a median age of 62 years were enrolled. As of the data cut-off date on 28 March 2024, the ORR assessed by IRC was 47.9% (56/117; 95% confidence interval: 38.5-57.3%). The incidence of treatment-related adverse events (TRAEs) of any grade was 97.5% (116/119). The incidence of grades 3 and 4 TRAEs was 38.7% (46/119). A total of 5.0% (6/119) of patients discontinued the treatment due to TRAEs. No treatment-related deaths occurred. Glecirasib exhibited promising clinical efficacy and manageable safety profiles in these patient populations. ClinicalTrials.gov identifier: NCT05009329 .

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03401-z

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 32 references

Cited by

See all 43

Metadata

Authors
Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., Yang, R., Wang, Z., Zhao, E., Wang, M., Zhao, Y., Tang, K., Li, Z., Song, Z., Li, Y., Zhuang, W., Jin, B., Cheng, Y., Hu, Y., Gu, Y., Wu, L., Ma, R., Yu, Q., Yu, Y., Zhao, J., Zhao, H., Lv, D., Shang, Y., Xing, P., Zhou, J., Li, X., Liu, Z., Dai, Z., Xia, G., Chen, X., Ba, Y., Bai, C., Li, Q., An, G., Hu, W., Wang, Y., Wang-Gillam, A., Ding, Y., Li, Q., & Rao, Z.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Peking University Cancer Hospital (CN)
  • Shandong Tumor Hospital (CN)
  • First Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Fudan University Shanghai Cancer Center (CN)
  • Qilu Hospital of Shandong University (CN)
  • West China Hospital of Sichuan University (CN)
  • First Affiliated Hospital of Nanchang University (CN)
  • Capital Medical University (CN)
  • Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province (CN)
  • Peking Union Medical College Hospital (CN)
  • Henan Cancer Hospital (CN)
  • The First Affiliated Hospital, Sun Yat-sen University (CN)
  • Zhejiang Cancer Hospital (CN)
  • Chongqing Cancer Hospital (CN)
  • Fujian Provincial Cancer Hospital (CN)
  • First Hospital of China Medical University (CN)
  • Jilin Province Tumor Hospital (CN)
  • Hubei Cancer Hospital (CN)
  • Jiangsu Province Hospital (CN)
  • Hunan Cancer Hospital (CN)
  • Liaoning Cancer Hospital & Institute (CN)
  • Guangxi Medical University (CN)
  • Third Affiliated Hospital of Harbin Medical University (CN)
  • Second Affiliated Hospital of Anhui Medical University (CN)
  • Affiliated Hospital of Hebei University (CN)
  • Sichuan Cancer Hospital (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Dalian Medical University (CN)
  • Jiangsu Cancer Hospital (CN)
  • Hangzhou Cancer Hospital (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Chengde Medical University (CN)
  • Renmin Hospital of Wuhan University (CN)
Corresponding author
Shi, Yuankai
Venue
Nature Medicine
Published
2025-01-06
Volume
31
Issue
3
Pages
894-900
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4406104531
Cited by
42
References
32
Citations by year
2026: 23 · 2025: 19
FWCI
27.41
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Academy of Medical Sciences
  • Chinese Academy of Sciences
  • Chinese Academy of Medical Sciences
  • Peking Union Medical College
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
KRAS G12C mutation, non-small cell lung cancer, KRAS G12C inhibitors, covalent inhibitors, oral targeted therapy, objective response rate, treatment-related adverse events, metastatic lung cancer, locally advanced lung cancer
MeSH terms
Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. https://app.cochat.ai/papers/10.1038/s41591-024-03401-z
The paper
Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., Yang, R., Wang, Z., Zhao, E., Wang, M., Zhao, Y., Tang, K., Li, Z., Song, Z., Li, Y., . . . Rao, Z. (2025). Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03401-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.